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Background/Aims: Helicobacter pylori infection causes gas-
tritis, peptic ulcers and gastric malignancies, and its eradica-
tion has been advocated by many groups. We determined the 
H. pylori carrier status and eradication rates of patients with 
chronic hepatitis C virus (HCV) infection. Methods: In total, 
76 chronically HCV-infected patients were enrolled for com-
parison with 228 HCV-noninfected, age- and sex-matched 
controls. H. pylori infection was confirmed by H. pylori anti-
body and urea breath testing. Results: The H. pylori infection 
rate was significantly higher for HCV-infected patients (67 
of 76, 88.2%) than for HCV-noninfected controls (158 of 
228, 69.3%). Endoscopic ﬁ  ndings showed that the rates of 
gastric ulcers and gastritis were significantly higher for the 
67 HCV-infected patients with H. pylori infection (34.3% and 
77.6%) than for the 158 HCV-noninfected controls with H. 
pylori infection (15.2% and 57.6%). Treatment to eradicate H. 
pylori had a signiﬁ  cantly higher success rate for HCV-infected 
patients (61 of 67, 91.0%) than for HCV-noninfected con-
trols (115 of 158, 72.8%). Conclusions: The markedly high 
H. pylori eradication rate observed in this study shows that 
eradication of H. pylori holds promise for the improvement of 
the long-term health condition of patients with chronic HCV 
infection. (Gut Liver 2011;5:447-453)
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INTRODUCTION
Helicobacter pylori (H. pylori) infection is one of the most 
common bacterial infections in the world.
1,2 This infection is 
caused a by spiral shaped gram-negative bacillus that colo-
nizes the superficial area of the mucous gel layer of the human 
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stomach. This bacterium has been implicated in the etiology of 
chronic active gastritis; peptic ulcer disease, gastric cancer and 
mucosa-associated lymphoid tissue lymphoma, and virtually all 
patients infected with H. pylori who have endoscopic biopsies 
are found to have histologic gastritis.
3,4
In 1994, the World Health Organization classified H. pylori as 
a grade I carcinogen,
5 and approximately 50% of all humans in-
fected with H. pylori.
6 H. pylori infection increased significantly 
with age and male sex in our previous study.
2 The prevalence 
of H. pylori infection increases with age but is quite different 
among various populations. H. pylori infection is more preva-
lent in groups of low socioeconomic status, so the overall anti-
body to H. pylori prevalence in developing countries is higher 
(60% to 80%) than in developed countries (40%).
4,7-12 Most 
people infected with H. pylori probably acquired the infection 
in childhood when standards of living and sanitation, such as 
public water systems, were not well developed.
1-5,13 A decrease 
in the frequency of a disease in successive generations (i.e., birth 
cohorts) is most likely due to changes in such environmental 
factors.
14 In fact, the high prevalence (over 60%) of H. pylori in 
Japanese aged over 50 years is most likely due to poor environ-
mental conditions during the period of turmoil just after World 
War II.
2 Eradication of H. pylori is the recommended treatment 
to cure peptic ulcers and to prevent ulcer complications.
15 Triple 
therapy with a proton pump inhibitor (PPI), clarithromycin 
(CAM), and amoxicillin (AMOX) is an effective regimen for the 
eradication of H. pylori.
13
Chronic hepatitis C virus (HCV) infection is a leading cause 
of end-stage liver disease worldwide.
15,16 In Japan, the general 
prevalence of HCV infection is about 1%, but 50- to 70-year-old 
persons have a very high rate of infection.
16 Chronic HCV infec-
tion causes several problems related to gastric and esophageal 448  Gut and Liver, Vol. 5, No. 4, December 2011
diseases, such as hyper-portal gastritis and varices. It has been 
demonstrated that patients with liver cirrhosis are frequently 
subject to a number of disorders of the gastric mucosa, and pep-
tic lesions in the gastroduodenal mucosa have been observed 
more often in cirrhotic patients than in controls.
17 However, 
little information is available on the relationship of the gastro-
duodenal lesions and H. pylori infection of patients with chronic 
HCV infection. Also, there are very few studies of the H. pylori 
eradication rates for these patients.
To address the above issues, the present case control study 
was done to determine the persistent H. pylori infection rate and 
the eradication treatment response, by H. pylori-related endo-
scopic findings, of patients with chronic HCV infection and a 
control group of HCV-uninfected persons.   
MATERIALS AND METHODS
1. Patients
The present study consisted of 76 patients with chronic HCV 
infection and 228 HCV-noninfected control subjects living in 
Fukuoka who received esophagogastroduodenoscopy in Ky-
usyu University Hospital between January 2005 and January 
2010. Of the 76 HCV infected patients, none had hepatic cell 
carcinoma or severe liver dysfunction such as ascites or hepatic 
encephalopathy. Also, 23 patients had histologically confirmed 
cirrhosis of Child-Pugh class A, but none were of Child-Pugh 
classes B or C. The present study was a part of an epidemio-
logical study of the changes of H. pylori infection prevalence 
in the Japanese general population that surveyed over 4,700 
residents who participated in a general health checkup program 
over the last 2 decades.
2 Over 1,000 participants with antibody 
to H. pylori (anti-H. pylori) positive in the ongoing study who 
visited our hospital to check for persistent H. pylori infection 
underwent endoscopic examination. Of them, 228 age and sex 
matched HCV-noninfected control subjects were randomly se-
lected for comparison.
To ensure the validity of the data, all doctors carrying out 
the study were staff members of our department trained in the 
study protocol. All patients and controls were given a thorough 
medical history interview, clinical examination, abdominal 
ultrasound and laboratory investigations, including complete 
blood counts, total bilirubin (TB), serum total protein (TP), se-
rum albumin (Alb), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALP), serum cre-
atinine, and prothrombin time (PT) at a commercial laboratory 
(MBC Laboratory, Tokyo, Japan). Hepatitis B surface antigen 
(HBsAg) and antibody to HCV (anti-HCV) were tested by com-
mercial enzyme-linked immunosorbent assay (ELISA) kits and 
reverse transcriptase polymerase chain reaction assay for serum 
HCV RNA (COBAS Amplicor HCV Monitor Test v2.0; Roche 
Diagnostics, Tokyo, Japan). All patients were positive for anti-
HCV and HCV RNA and negative for HBsAg. All control sub-
jects were negative for both HCV and HBV infection. Persistent H. 
pylori infection was defined as positive for serum anti-H. pylori 
and 13C-urea breath test (UBT). All patients and control sub-
jects were interviewed by our staff doctors about the presence 
of dyspepsia (bothersome postprandial fullness, early satiation, 
epigastric pain, and epigastric burning), based on the Rome III 
criteria. The dyspeptic symptoms had to be present for more 
than 3 days a week for at least 6 months. Informed consent was 
obtained from all patients and controls before enrollment. The 
present study was carried out in accordance with the principles 
of the Declaration of Helsinki as revised in 2000.
2. Persistent H. pylori infection
Serum samples were collected from all patients and control 
subjects, separated and stored at -80
oC until testing for routine 
serum biochemistry. Anti-H. pylori was measured in serum 
using an ELISA (E plate Eiken Disk H. pylori antibody; Eiken 
Chemical Co., Tokyo, Japan). An antibody concentration ≥10.0 
ELISA value in the assay indicates anti-H. pylori IgG positivity.
Urea breath test to confirm persistent infection was done 
only for patients and control subjects with anti-H. pylori posi-
tive. Patients and control subjects fasted for at least six hours 
before this test, after which a first breath sample was collected. 
A 100 mg 13C-urea tablet (UBiTkit; Otsuka Pharmacuetical Co., 
Ltd., Tokyo, Japan) was then administered orally, and a second 
breath sample was collected 20 minutes later. The collected 
samples were analyzed using an isotope-selective nondispersive 
infrared spectrometer (UBiT-IR300; Otsuka Pharmacuetical Co., 
Ltd.). The cut-off value of ECR used for H. pylori eradication 
was 2.5‰. The urea breath test was used for the diagnosis of 
persistent H. pylori infection at enrollment and to confirm suc-
cessful eradication.   
3. Esophagogastroduodenoscopy   
All patients and control subjects underwent esophagogastro-
duodenoscopy at enrollment. Four experienced endoscopists of 
our hospital performed each examination without knowledge of 
any data of the studied patients. Endoscopic diagnosis included 
erosive reflux disease, gastritis, gastric ulcer, duodenal ulcer, 
and gastric cancer, based on the judgment of the four endosco-
pists.
4. Histological examination   
Needle biopsy of the liver was done only for 76 patients with 
chronic HCV infection. Two pathologists did the histopathologi-
cal assessment separately, and then a consensus between them 
was made on discordant assessments. The pathologists were not 
aware of the clinical data, at the time of assessment. The Meta-
vir fibrosis score was used to evaluate histological fibrosis from 
F0 to 4: F0, no scarring; F1, minimal scarring; F2, scarring has 
occurred and extends outside the areas in the liver that contains 
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to other areas that contains fibrosis; F4, cirrhosis or advanced 
scarring of the liver.
18 Of the 76 patients, none, 20, 19, 14, and 
23 were assigned as F0, F1, F2, F3, and F4, respectively.   
No histological examination was done for HCV-noninfected 
controls. For the HCV-noninfected controls, the presence or 
absence of cirrhosis was judged by the results of the following 
markers: platelet counts, PT, and serum levels of TP, Alb, TB, 
AST, ALT, ALP, and type IV-collagen.   
5. H. pylori eradication protocol   
The triple drug combination therapy for H. pylori eradication 
included lansoprazole 60 mg b.i.d., clarithromycin (CAM) 800 
mg b.i.d., and amoxicillin (AMOX) 1,500 mg b.i.d. for seven 
days. The successful eradication of H. pylori was defined as 
negative for urea breath test at 24 weeks after the therapy (Fig. 
1). Patients and control subjects were instructed to refrain from 
any antibiotics for at least four weeks and from PPIs for at least 
eight weeks before testing for the eradication response to mini-
mize the chance of false negative results by urea breath test.   
6. Statistical analysis   
The rate of successful H. pylori eradication was determined 
by intention-to-treat and per-protocol analysis. Statistical 
analysis was done with SPSS for Windows version 16.0 (SPSS 
Inc., Chicago, IL, USA). Continuous data were expressed as 
mean±standard deviation. Continuous values were analyzed 
using the Student’s t-test. Categorical variables were analyzed 
using the chi-square test, Fisher’s exact test, or trend test. A p-
value of less than 0.05 was regarded as statistically significant.   
RESULTS   
Table 1 shows the characteristics of the 304 studied patients 
and control subjects. The persistent H. pylori infection rate 
was significantly higher for the 76 patients with chronic HCV 
infection (88.2%) than for the 228 HCV-noninfected controls 
(69.3%) (p=0.0020). No significant differences in the H. pylori 
infection rate were found among the 76 HCV-infected patients 
with F0-1 (n=20), F2-3 (n=33), and F4 (n=23) classifications by 
histological fibrosis; 90.0%, 87.8%, and 86.9%, respectively. The 
frequency of dyspeptic symptoms did not significantly differ be-
tween the patients with chronic HCV infection (9 of 76, 11.8%) 
and the HCV-noninfected controls (25 of 228, 10.9%).   
Table 2 shows the clinical characteristics of 76 patients with 
chronic HCV infection, classified by H. pylori infection status. 
No significant differences were found in sex, age, HCV viral 
markers, or other parameters between patients with and without 
H. pylori infection.
Fig. 1. Protocol for Helicobacter py-
lori eradication treatment. 
Table 1. Clinical Characteristics of 76 Patients with Chronic HCV In-
fection and 228 Participants without HCV Infection
Characteristics
Chronic HCV infection
p-value Yes
(n=76)
No
(n=228)
Male, n (%) 42 (55.3) 126 (55.3) Matched
Age, yr 58.1±9.9 58.1±9.9 Matched
HCV genotype 1b, n (%) 49 (64.5) - -
HCV RNA level, kIU/mL 1,892.3±235.9 - -
HCV RNA level under 
  100 kIU/mL, n (%)
4 (5.3) - -
Alanine aminotransferase, 
  IU/L
90.2±12.5 23.6±7.9 <0.0001
Platelet count, ×10
4/μL 12.4±2.0 25.8±6.1 <0.0001
Liver cirrhosis, n (%) 23 (30.3) 0 <0.0001
Dyspepsia, n (%)   9 (11.8)   25 (10.9) 0.835
Perisitent Helicobacter pylori 
  infection, n (%)
67 (88.2) 158 (69.3) 0.002
Chronic HCV infection was defined as serum positivity for antibody 
to HCV and HCV RNA. Persistent Helicobacter pylori infection was 
defined as positivity for the antibody and urea breath test. Continu-
ous data are shown as the mean±SD.
HCV, hepatitis C virus.450  Gut and Liver, Vol. 5, No. 4, December 2011
Table 3 shows the endoscopic findings of the patients and 
controls, classified by H. pylori and HCV infection status. The 
rates of gastritis and gastric ulcer were significantly higher for 
the 67 HCV-infected patients with H. pylori infection (group 
A) (77.6% and 34.3%) than for the 158 HCV-noninfected con-
trols with H. pylori infection (group B) (57.6% and 15.2%) (all 
p<0.05) and for the 70 HCV-negative controls without H. pylori 
infection (group D) (32.8% and 4.3%) (all p<0.05). Classified by 
histological fibrosis, no significant differences were found in the 
rates of endoscopic findings of HCV-infected patients: 75.0%, 
72.7%, and 73.9% for gastritis; 35.0%, 30.3%, and 26.1% for 
gastric ulcer; and 10.0%, 12.2%, and 8.7% for duodeneal ulcer 
for the F0-1 (n=20), F2-3 (n=33), and F4 (n=23) stages, respec-
tively.
All of the 67 HCV-infected patients and 158 HCV-negative 
controls with H. pylori infection agreed to receive the eradica-
tion treatment after informed consent. The treatment was dis-
continued by three of the HCV-infected patients (2 diarrhea, 1 
eruption) and nine of the controls (3 diarrhea, 2 taste disorder, 
1 eruption, and 3 who dropped out). In an intention-to-treat 
analysis, the successful eradication rate of 91.0% (61 of 67) was 
significantly higher for the HCV-infected patients than the rate 
of 72.8% (115 of 158) for the controls (p=0.0043). Classified by 
stage of histological fibrosis, the eradication rates increased with 
the fibrosis score of HCV-infected patients: F0-1 (83.3%, 15 of 
18), F2-3 (93.1%, 27 of 29), and F4 (95.0%, 19 of 20), with no 
significant differences. The per-protocol analysis also showed 
a significant difference in the rate of successful eradication 
between the HCV-infected patients (61 of 64, 95.3%) and the 
controls (115 of 149, 77.2%) (p=0.0026).
DISCUSSION   
The present study showed a significantly higher rate of H. 
pylori infection and higher rates of gastric ulcer and gastritis 
for HCV-infected patients than for patients without HCV infec-
tion. Moreover, the rate of successful eradication was found to 
be markedly higher for the HCV infected patients than for the 
control patients without HCV infection. One Japanese report 
showed that coexistent H. pylori infection did not influence the 
clinical course of chronic hepatitis C.
19 However, there was one 
report from Egypt that H. pylori infection may reflect chronic 
liver damage by HCV infection.
20 To our best knowledge, this 
is the first study to demonstrate such a markedly high H. pylori 
Table 2. Clinical Characteristics of 76 Patients with Chronic HCV In-
fection, Classified by Persistent Helicobacter pylori Infection
Characteristics
Persistent Helicobacter pylori
infection
p-value
Yes
(n=67)
No
(n=9)
Male, n (%) 36 (53.7) 6 (66.7) 0.7231
Age, yr 57.7±9.1 59.1±12.9 0.8901
HCV genotype 1b, n (%) 43 (64.2) 6 (66.7) >0.9999
HCV RNA level, kIU/mL 1,892.3±235.9 2,104.0±301.6 0.7703
HCV RNA level under 
  100 kIU/mL, n (%)
4 (6.0) 1 (11.1) 0.4793
Alanine aminotransferase, 
  IU/L
89.3±11.3 93.6±15.6 0.6682
Platelet count, ×10
4/μL 12.3±1.9 12.8±2.1 0.8098
Liver cirrhosis, n (%) 20 (29.9) 3 (33.3) >0.9999
Dyspepsia, n (%)   8 (11.9) 1 (11.1) >0.9999
Histological finding of liver biopsy, n (%)
   F0-1 18 (26.9) 2 (22.2) >0.9999
   F2-3 29 (43.3) 4 (44.4) >0.9999
   F4 (cirrhosi) 20 (29.9) 3 (33.3) >0.9999
Persistent Helicobacter pylori infection was defined as positivity for 
the antibody and urea breath test. Chronic HCV infection was defined 
as serum positivity for antibody to HCV and HCV RNA. The Metavir 
fibrosis score was used to evaluate histological fibrosis from F0 to F4. 
Continuous data are shown as the mean±SD.
HCV, hepatitis C virus. 
Table 3. Differences in Endoscopic Findings and Eradication Treatment Rates of 76 HCV-Infected Patients and 228 HCV-Unifected Controls, Clas-
sified by Helicobacter pylori and HCV Infection Satus
Group
Persistent
Helicobacter 
pylori
infection
Chronic
HCV
infection
No.
Chronic gastritis
prevalence,
n (%)
Gastric ulcer
prevalence,
n (%)
Duodeneal ulcer
prevalence,
n (%)
Eradication 
treatment rate*,
n (%)
A Yes Yes   67 52 (77.6)
̉ 23 (34.3)
#   8 (11.9)   61 (91.0)
̈
B Yes No 158 91 (57.6)
§ 24 (15.2)** 12 (7.6) 115 (72.8)
C No Yes     9   4 (44.4)
∥   0
̈ ̈   0
D No No   70 23 (32.9)
¶   3 (4.3)
̉ ̉   0
Groups A and C consisted of 76 patients with chronic HCV infection. Persistent Helicobacter pylori infection was defined as positivity for the an-
tibody and urea breath test. Chronic HCV infection was defined as positivity of antibody to HCV and HCV RNA in the serum.
HCV, hepatitis C virus.
*Analyzed by intention-to-treat; 
̈Significantly higher than Group B patients (p=0.0043); 
̉vs 
§, p=0.0069; 
̉vs 
∥, p=0.484; 
̉vs 
¶, p<0.0001; 
# vs 
**, p=0.0023; 
# vs 
̈ ̈, p=0.0503; 
# vs 
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eradication rate for patients with HCV infection.
In comparison with worldwide data, the anti-H. pylori preva-
lence for the age groups under 40 years of our previous Japa-
nese report
2 was low (about 20%) and similar to those in the 
USA, France, the Netherlands, Finland, Wales, Australia, and 
other developed countries, but the prevalence in the age groups 
over 50 years were high (over 60%) and similar with those in 
Algeria, Ivory Coast, Vietnam, Thailand, Papua New Guinea, 
and Peru, which are developing countries.
2,13-19 In brief, most of 
our studied persons aged 50 or over years had a high probabil-
ity of having H. pylori infection in this area where the infection 
was historically widespread.
The most likely mode of H. pylori transmission is from person 
to person, by either the oral-oral (through vomit or possibly 
saliva) or fecal-oral route.
1,2 Also, the iatrogenic transmission 
of H. pylori or following endoscopy (gastric oral route) is com-
mon if the proper method of disinfection is not followed. HCV 
infection also has a worldwide distribution.   Most transmission 
of HCV is through the transfusion of blood or blood products, 
the transplantation of organs from infected donors, and through 
the sharing of contaminated needles among injection-drug us-
ers.
21 Sexual transmission has also been well documented.
22     
Although H. pylori and HCV have entirely different routes of 
transmission, we found a higher rate of H. pylori infection 
among patients with chronic HCV infection than among HCV-
uninfected persons. Usually, most H. pylori infection is acquired 
during childhood,
2 while HCV infection occurs at any age.
21 The 
following hypothesis might explain the higher H. pylori infec-
tion rate of patients with HCV infection in the present study. 
Patients with chronic HCV infection display impaired virus-spe-
cific CD4
+ and CD8
+ T cells with lower proliferative and gamma 
interferon (IFN γ)-producing capacities,
22 which leads to T cell 
dysfunction. This may contribute to increased susceptibility to 
secondary microbial pathogens, including viruses, bacteria, and 
parasites,
23 thus possibly increasing the risk of H. pylori infec-
tion. H. pylori possibly evades host responses through the inhi-
bition of antigen specific T cell proliferation,
24 major histocom-
patibility complex class II-restricted, cell-mediated mechanisms 
that control H. pylori infection,
25 or adoptive transfer of CD4
+ T 
cells that have been demonstrated to have a protective role of T 
cells. In spite of good host immune responses, some bacteria are 
not cleared and a chronic infection can be established.
26
We found significantly higher rates of gastric ulcer and gas-
tritis for HCV-infected patients with H. pylori infection than 
for HCV-negative persons with H. pylori infection. In the late 
1980s, it became apparent that there was a very close associa-
tion between chronic active gastritis and colonization with H. 
pylori. The major genetic determinant of H. pylori virulence is 
the cag Pathogenicity Island (cag PAI), which encodes a type 
IV secretion system that allows an immunodominant antigen, 
CagA, to be translocated into gastric epithelial cells.
27 In com-
parison to infection with cag PAI-negative H. pylori strains, 
infection with cag PAI positive strains is associated with an in-
creased severity of gastric mucosal inflammation, an increased 
risk for the development of peptic ulceration, and an increased 
risk of gastric cancer.
28 It is important that H. pylori infection 
can alter acid secretion in both directions.   Meanwhile, chronic 
liver disease has several problems related to gastric and esopha-
geal diseases, such as hyperportal gastritis and esophageal and 
gastric varices.
17 The most important pathogenesis factor of 
gastroduodenal lesions in end stage liver disease and cirrhosis 
is portal hypertension. This causes splenic congestion, which, 
at least in theory, might interfere with the normal reparative 
processes of the gastroduodenal mucosa, leading to increased 
susceptibility to acid and pepsin secretion.
17 Changes in gastric 
microcirculation in cirrhosis, such as increased straight arteri-
oles and dilated pre-capillaries as well as capillaries and veins, 
have been reported.
17 These alterations are probably related 
to portal hypertension and might contribute to acid peptic le-
sions.
29 However, there was no significant difference in the rates 
of gastric ulcer and gastritis between our cirrhotic and noncir-
rhotic HCV infected patients with H. pylori infection, possibly 
because our study was too small to clarify the difference. 
Eradication of H. pylori is very efficacious in the treatment of 
upper gastrointestinal disease.
30,31 The standard strategy for the 
cure of H. pylori infection includes a triple drug combination 
therapy of a PPI, AMOX, and CAM or metronidazole
30-32 but the 
development of resistance by H. pylori to the latter two drugs 
has been reported.
33,34 Eradication success depends mainly on 
the patient’s adherence to treatment and bacterial resistance to 
medications. In Japan, CAM consumption multiplied by four be-
tween 1993 and 2000. This can be explained by the widespread 
use of CAM in Japan, suggesting resistance to the drug.
35 The 
present study showed successful eradication rates of 91.0% for 
HCV-infected patients and 72.8% for HCV-uninfected controls 
by intention-to-treat analysis. This result might be interpreted 
by the role of liver disease on the metabolism of PPI. A PPI is 
an important drug in the triple therapy used for the eradication 
of H. pylori because of its action in inhibiting acid formation by 
blocking (H
+/K
+)-ATPase of the stomach parietal cells after be-
ing transformed into an active form under acidic conditions.
36 
Its catabolism in the liver depends mainly on an isoenzyme 
of cytochrome P450 2C19. It has two genetically determined 
phenotypes in humans: extensive metabolizers and poor me-
tabolizers.
37 Phenotype variation affects the acid suppressing 
effects of omeprazole by changing its rate of catabolism.
37 The 
frequency of the poor metabolizer genotype is much higher in 
Japanese populations (18.8%) than in Caucasian populations 
(2.1%). Some studies have shown that PPI metabolism is af-
fected by many factors, such as gender,
38 age and concomitant 
use of other drugs.
39 These factors are usually associated with a 
decrease in liver function. Although it is very hard to determine 
the precise mechanism, the disorder of liver function by chronic 
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which may explain the high eradication rate of H. pylori of 
HCV-infected patients.
The present study has certain limitations. First, screening of 
H. pylori infection was determined only by serum antibody. 
The first aim of this study was to investigate persistent H. pylori 
infection in HCV-infected patients defined by a urea breath test 
with a higher sensitivity and specificity. Therefore, further stud-
ies are needed to find an association between anti- H. pylori 
negativity and urea breath test positivity among HCV-infected 
patients. Second, no information on antibiotic resistance to H. 
pylori was available. We did not perform H. pylori culture or 
minimum inhibitory concentration (MIC) test before the triple 
therapy regimen because they require intensive labor, are pro-
hibitively costly, and it was difficult to obtain patient consent 
to biopsy gastric tissues for the MIC test. In fact, the eradication 
rates with conventional PPI-based triple therapy have become 
unacceptably low over the last decade due to increasing resis-
tance to antibiotics.
40 The resistance rates probably depend on 
the area studied and whether or not the participants are resi-
dents of the same area. The present investigation was a compar-
ison between HCV-infected patients and HCV-uninfected con-
trols who had lived in close proximity to our hospital. Therefore, 
no difference in resistance was expected between them.
In conclusion, H. pylori-related gastric diseases are a serious 
problem for patients with chronic HCV infection. The markedly 
high H. pylori eradication rate observed in this study shows that 
eradication of H. pylori holds promise for the improvement of 
the long-term health condition of these patients.   
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